confidential 1

Swiss Medica Inc.Raghu Kilambi, C.A., Chief Executive Officer

EUROPE 2005

(OTCBB: SWME)

PATENTED, CLINICALLY TESTED, OVER-THE-COUNTER, NATURAL

CHRONIC AILMENT SOLUTIONS

confidential 2

Disclaimer

Statements in this release that relate to future plans, events or performance are forward-looking statements reflecting management's current expectations, assumptions and estimates of future performance and economic conditions. All forward-looking statements are made in reliance on the safe harbor provisions of the Securities Act of 1933 and the Securities Exchange Act of 1934. The company cautions investors that forward-looking statements involve risks and uncertainties that may cause actual results to differ materially from those expressed or implied in such statements. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

The estimates and statements contained in this presentation were prepared on the basis of assumptions and hypotheses which the Company believes to be reasonable but which are subject to substantial risks, uncertainties and contingencies, some of which are difficult to predict and beyond the control of the Company, and which may result in substantial modifications. No assurance can be given as to the availability of any of the potential benefits described in this presentation and such information should not be construed as a representation or prediction that the Company will achieve or is likely to achieve any particular results.

The assumptions and projections have neither been compiled, reviewed, nor audited by the Company’s independent certified public accountants and do not constitute a “Financial Forecast” or a “Projection” as defined by the American Institute of Certified Public Accountants. All figures used in the presentation are in US dollars.

confidential 3

Strategic Opportunity

Highlights• Patented, Clinically -Tested All Natural Over-The-Counter products • Elite OTC chronic ailment solutions NOT vitamins / supplements• 3 Products targeting multi-billion $ pain relief and anti-depression markets• Replace / reduce the use of prescription and OTC products with side effects• Penetration in 19,000 doors and growing in leading North American retailers

Period Ending Q2/2005A Q1/2005A FY 2004

Revenue $1.38 million $1.13 million $0.6 million

Gross Margins 1.13 million 0.94 million 0.5 million

EBITDA $(0.48) million ($1.22) million ($3.32) million

Market Cap (09/26/05) $20.0 Million

Common Shares (O/S) 105 Million

Common Shares (F/D) 121 Million

52-Week Range

Current Stock Price (09/26/05)

$0.46 - $0.06

$0.20

confidential 4

Industry Market ShareChronic Pain Market

350 million adults worldwide suffer from Arthritis and chronic pain, in some form. In the United States alone: 45 million + suffer from

Osteoarthritis 10 million + suffer from

Fibromyalgia 5 million + suffer from

Rheumatoid Arthritis

65 million Americans suffer from back pains and aches every year. Four of five adults will suffer back pain at some point in their lifetime.

Aging population will increase incidence of arthritic conditions.

Additional conditions: Gout, Tendonitis, injuries, back pain, foot pain, neck pain, shoulder pain, etc

46%

23%

5%

26%

Osteoarthritis FibromyalgiaRheumatoid Arthritis Other

Chronic Pain Suffers (percentage)

confidential 5

Industry Market ShareChronic Pain Remedies Market

In 2004, the worldwide market for pain relief products was estimated at $30 billion.

Dominated by Rx/OTC pills Prescription pills $23

billion OTC pills $7 billion

Consumers increasingly concerned about side effects and mixing prescription medications.

Consumers increasingly desire to self-treat pain relief and other conditions.

Prescription74%

OTC19%

Other7%

Estimated Worldwide Pain Relief Remedies

(percentage)

confidential 6

Drug Industry ConcernsTroubles in $18 Billion Chronic Pain Market

September 30, 2004: Merck & Co. withdraws Vioxx® Leading prescription pain pill: $2.5 billion revenues.

April 7, 2005: FDA requests that Pfizer withdraw Bextra® from the market Also, requires Pfizer to include a boxed warning in the Celebrex label.

July 22, 2005: PAIN MEDICINE; Survey on physician perception of Cox-2 Inhibitors In the wake of the withdrawal of Vioxx and Bextra from the market, fewer than

one in five primary care physicians plan to prescribe COX-2 Inhibitors for treating chronic pain according to a nationwide survey by Pri-Med Institute.

April 7, 2005, The FDA required that the package insert of all NSAIDs (excluding aspirin) be revised to include a “boxed” or serious warning to highlight the potential increase risk of cardio-vascular events.

Pain Relief Market has new window open for a safe, natural topical alternative

confidential 7

O24 Overview

US-Patented, all natural, essential oil topical pain relief product line 7 essential oils, patented binding process that eliminates artificial binders

that reduce absorption and efficacy

Proven relief World class sports and medical endorsements from Europe, USA and

Canada Extensive hospital, physician, pain clinic, chiropractor use

Medical & Double-Blind Clinical studies from Europe and North America

Previously used in Europe for athletes and doctors/hospitals

2 products: O24 Pain Neutralizer and O24 Fibromyalgia

confidential 8

O24 – Natural IngredientsPatented binding process – No chemicals

confidential 9

O24 Medical Studies

confidential 10

Competitive Product TypesO24 vs Other Pain Relief Products

O24 OTC Drugs

Patented √ √All Natural √Lasting Relief √ √Medical Studies √ √ √Endorsements √ √ √No Side Effects √ Economical √ √Fast Acting √

confidential 11

Retail DistributionCurrently in more than 19,000 stores

confidential 12

Swiss Medica Quarterly Store CountCurrently > 19,000 stores

02,0004,0006,0008,000

10,00012,00014,00016,00018,00020,000

Q4 04 Q1 05 Q2 05 Q3 05 Q4 05

confidential 13

O24 Fibromyalgia

Fibromyalgia syndrome (FMS) is estimated to affect between 2 to 4% of the world's population Is the second most commonly diagnosed disorder in rheumatology clinics, second only to

osteoarthritis An estimate 10-million American have been diagnosed with Fibromyalgia

Widespread and Chronic Pain Often effects all parts of the body Deep muscular aching, throbbing, twitching, stabbing and shooting pain

Symptoms include: Pain, including tenderness on pressure points Fatigue Sleep Disorders Headaches

Current pain treatment include acetaminophen or ibuprofen

No other clinically tested product available in North American pharmacies

confidential 14

O24 Fibromyalgia

O24 Fibromyalgia is the FIRST product marketed specifically for Fibromyalgia pain to be available in North American pharmacies. It is a patented formula made from seven essential oils and has been clinically tested and shown to be an effective and safe pain reliever.

O24 Fibromyalgia is the FIRST and only product to earn the coveted National Fibromyalgia Association’s Seal of Approval. The NFA has 2,000 affiliated support groups and sphere of influence of 1 million people.

A double-blind clinical study conducted at University of Toronto found that 90 percent of patients who used O24 Fibro reported mild to markedly better improvement versus only 7 percent who were given a placebo. A full 54 percent reported moderate to markedly better improvement

Launches in North American pharmacies and retailers in fourth quarter 2005.

confidential 15

O24 Fibromyalgia – Q4 LAUNCH

confidential 16

Industry Market Share Anti-Depressant Market

28 million people in the US have taken an anti-depressant

400+ million adults worldwide suffer from some form of depression

Worldwide drug market for depression treatment is more than $17 billion: Prescription Drugs –

90% of the market(significant side effects)

OTC Products – 10% of the market(no proven treatments)

Swiss Medica will launch safe, clinically proven alternatives to current Drugs and OTC products

90%

10%

Rx OTC

Worldwide $17 billion Anti-Depression Market

(percentage)

confidential 17

PMS Escape Market Opportunity

200 million women worldwide suffer from mood and appetite symptoms associated with Premenstrual Syndrome (PMS)

PMS Escape is the only clinically proven OTC product to address these conditions 100% drug-free Pleasant tasting powered drink

mix Carbohydrate / nutrient blend

PMS mood market opportunity is estimated at more than $2 billion

World Class inventors of PMS Escape also invented Serafem, the only prescription drug for PMS mood symptoms

Swiss Medica’s newly acquired ADBSI division will address the PMS market and expand to anxiety and stress related treatments

Severe20%

Moderate50%

Mild30%

PMS Intensity Level(percentage)

confidential 18

PMS ESCAPE

confidential 19

PMS Escape: World-Class Clinical Studies

confidential 20

Senior Management

Raghu Kilambi, C.A., Chief Executive Officer, Co-FounderChartered Accountant, seasoned executive and merchant banker

Co-founder of FutureLink, raised US$225 million of equity and built a $140 million revenue business with a peak market cap of $2 billion

Grant Johnson, President & COO, Co-FounderSeasoned operational & sales executive with a strong track record in selling

consumer products & services; Experienced in building sales and delivery teams

Bruce Fairbairn, Chief Financial Officer Operational finance at Canadian subsidiaries of NYSE-listed companies including

CFO of both public and private Companies

Thomas Quinn, Executive Vice President, US OperationsExtensive experience in sales management and product launches with

pharmaceutical and consumer packaged goods leaders including Procter and Gamble and Warner Lambert

confidential 21

Senior Management

Robert Esson, VP Robert Logistics and Supply Chain ManagementSenior Operations and Logistics executive with experience in consumer products

(Quaker Oats) & cosmetics (BeautiControl Cosmetics).

Wendy Kramer, Vice President Anti-Depression BiohealthExtensive background in generating new business for pharmaceutical and consumer

healthcare Companies including Allegan, Inc. Mead Johns Johnson Laboratories and Warner Lambert/Parke Davis.

Rob Klein, Vice President Strategy10+ years in strategic planning, budgeting, financing and business development for

various technology companies. In addition, was a ranked stock analyst covering Canadian Internet technology sector.

Anne Dundon, Vice President Canadian SalesStrong consumer marketing experience in both consumer packaged goods (Proctor &

Gamble, Revlon, and Bonnie Bell) and healthcare (Merck).

confidential 22

Sales and Marketing Strategy

DTC

• Radio Talk Shows

• TV, Newspaper, Magazine Editorials

• Sampling and Store Demos

• Targeted Advertising to Seniors & Minorities

ENDORSEMENTS

• Athletes, Trainers

• Celebrities

OPINION LEADERS

• Doctors

• Pharmacists

• Chiropractors

• Physiotherapists

RETAILERS

• Co-op Ads

• Detailing Pharmacists

• Displays

Consumers

confidential 23

Product Sampling

confidential 24

PR oriented Radio Marketing

confidential 25

Print Endorsements of O24

confidential 26

O24 in the News

confidential 27

Manufacturing & Regulatory Standards

Using FDA-certified contract manufacturers to manufacture O24 and PMS Escape

USA Regulatory:O24 Classified as OTC drug: oversight of FDA/FTCFDA monograph controls O24 claims

PMS Escape is approved for sale in the United States under the DSHEA regulations (Dietary Supplement)

Canada Regulatory:OTC: Health Canada NHP registration for O24 and PMS Escape

confidential 28

Growth Strategy

Enhance Product Portfolio: Depression, stress product (organic) Cholesterol, Diabetes, Heart Ailments

Professional Channel Distribution: Pain Clinics, Chiropractors, hospitals, other professionals

Physician, Pharmacist Detailing: Trade shows, samplers, conference speakers

International Distribution:

Insurance Reimbursement

confidential 29

Summary

Elite, Patented, Clinically-Tested Natural Products for Chronic Ailments

Drug /OTC Pain Relief & Depression markets have major side effect concerns

Huge opportunity to capitalize on concerns about drug safety

Expanding North American national retail presence

Robust marketing campaign focused on sampling and public relations

Growth from Professional Channels, additional products, international

distribution, insurance reimbursement

Strong management team with significant experience

Significant revenue growth / EBITDA positive by Q4 2005

Sept 26th Market Cap: US$20million

confidential 30

Comparable Valuations

Public Companies Company

Description

Year

End

Price 7/25/05

Market Cap ($ million)

P/E LQA

P/E FY

2005E*

P/Sales

(TTM)

Chattem (CHTT)

OTC

Products

Nov 46.58 921.5 19.4x 20.3x 3.33x

Cypress Bioscience

(CYPB)

Fibromyalgia

Phase III Clinicals

Dec 13.50 410.5 NM NM 28.8x

Biophan Techn.

(BIPH.OB)

Biotech Patents Feb 2.88 214.9 NM NM No Revenue

Paincare Holding

(PRZ)

Pain Mgmt

Centers

Dec 4.18 215.3 26.1x 16.0x 4.76X

CV Technologies (CVQ.T)

Patented

OTC Products

Sep 2.28 226.4 22.8x NA 11.3X

confidential 31

Contact

Contact

Chief Executive Officer:

Raghu Kilambi(416) 362-5775rkilambi@swissmedica.com

Investor Relations:

David Jones(705) 495 0022

djones@swissmedica.com

www.swissmedica.com www.O24zone.com www.pmsescape.com